eligibility_summary
Adults ≥18 with relapsed/refractory osteosarcoma or other sarcomas after 1L therapy, measurable disease (RECIST 1.1), tumor tissue/blood, ECOG 0–1, life expectancy ≥12 wks, contraception, not pregnant, consented. Exclude: prior B7‑H3, recent therapy/radiation/surgery, CNS mets/effusions, CYP3A4 or QT‑risk drugs, unresolved >G2 AEs, other malignancy, major organ/marrow or CV disease, uncontrolled diabetes/HTN, bleeding/thrombosis, serious infection or active viral/TB, and other unsafe factors
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: HS-20093, a fully humanized IgG1 antibody-drug conjugate (ADC) given IV every 3 weeks (8 or 12 mg/kg in Phase 2a, recommended dose in Phase 2b). Mechanism of action: Binds B7-H3 (CD276) on tumor cells, upon binding and internalization, the ADC delivers a cytotoxic payload to kill B7-H3–expressing cells. Cells/pathways targeted: B7-H3, a B7 family immune checkpoint molecule widely expressed on solid tumors, here specifically osteosarcoma and other bone/soft-tissue sarcomas, primary targeting is B7-H3–positive tumor cells. The study evaluates HS-20093 monotherapy efficacy, safety, PK, and immunogenicity in relapsed/refractory osteosarcoma and other sarcomas.